Follow Us on Google
By Bimbola Oyesola
Nigeria’s troubled economy has suffered another major blow as Johnson & Johnson Innovative Medicines (J&J) prepares to exit the country, raising fresh concerns about the worsening investment climate and its ripple effects on the nation’s healthcare sector.
This for organised labour is a disorienting news as more Nigerian workers in the industry may be rendered redundant.
Reliable sources confirmed to the Commerce and Industry Correspondents Association of Nigeria (CICAN) that the decision was driven by the country’s deteriorating economic conditions, spiralling inflation, foreign exchange scarcity, rising operational costs and policy uncertainty.
For decades, J&J has supplied vital pharmaceutical and medical products to the Nigerian market, especially in critical areas such as oncology, immunology and mental health care. But the company, like many other multinationals, has found it increasingly difficult to sustain operations.
“Over the past one year, they had reduced their staff strength to about 20%, shrinking significantly,” a source disclosed. “In 2022, the Consumer Healthcare arm of the company had also quietly left the country.”
The departure of such a global healthcare leader is viewed by analysts as a red flag for foreign investors already wary of Nigeria’s unstable economic environment. “When a company like Johnson & Johnson cannot survive in Nigeria, it sends a troubling signal,” one source said. “It tells the world that doing business here is simply too risky.”
Industry observers warn that J&J’s exit will leave a noticeable gap in Nigeria’s healthcare supply chain. Patients battling cancer, autoimmune conditions, and mental health challenges may face limited access to life-saving medicines, as local production capacity remains weak.
“This is not just about jobs being lost,” another industry expert explained. “It is about Nigerians’ access to essential treatments. If multinational suppliers continue to withdraw, the country could face a severe healthcare supply crisis.”
The exit also threatens to undermine confidence in Nigeria’s ability to attract and retain foreign direct investment (FDI). In recent years, several global firms across consumer goods, oil and gas, and pharmaceuticals have either scaled back or completely shut down their Nigerian operations.
Economists argue that Nigeria’s business environment has become hostile due to multiple taxation, erratic policy shifts, and an unstable currency market. “Without urgent reforms, more multinationals will close shop, and the consequences for employment, investment, and healthcare access will be devastating,” warned Dr. Ahmed Adebayo, a Lagos-based economist.
Calls are growing for the federal government to stabilize the naira, reduce inflationary pressures, and introduce investor-friendly policies. Stakeholders insist that without deliberate intervention, Nigeria risks losing both the confidence of foreign investors and the trust of its citizens.
The departure of Johnson & Johnson adds to a growing list of multinational exits, including companies in the consumer goods and pharmaceutical sectors, further compounding Nigeria’s economic woes.
As the country braces for the impact, one message resonates across boardrooms and hospital wards alike: Nigeria must urgently reform its economy to retain investors and safeguard access to essential healthcare or risk a deeper crisis. This undoubtedly is a call to action on the part of government.
